Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: GLP-1 receptor agonists, traditionally used for treating type 2 diabetes mellitus and obesity, have demonstrated anti-inflammatory properties. However, their potential neuroprotective effects in neurodegenerative disorders remain unclear. OBJECTIVE: To evaluate the impact of GLP-1 receptor agonists on the risk of developing various neurodegenerative conditions in obese patients. METHODS: This comprehensive retrospective cohort study analyzed data from 5,307,845 obese adult patients across 73 healthcare organizations in 17 countries. Propensity score matching was performed, resulting in 102,935 patients in each cohort. We compared the risk of developing neurodegenerative disorders between obese patients receiving GLP-1 receptor agonist therapy and those who were not. RESULTS: Obese patients treated with GLP-1 receptor agonists showed significantly lower risks of developing Alzheimer's disease (RR = 0.627, 95 %CI = 0.481-0.817), Lewy body dementia (RR = 0.590, 95 %CI = 0.462-0.753), and vascular dementia (RR = 0.438, 95 %CI = 0.327-0.588). The risk reduction for Parkinson's disease was not statistically significant overall (RR = 0.784, 95 %CI = 0.580-1.058) but was significant for semaglutide users (RR = 0.574, 95 %CI = 0.369-0.893). Semaglutide consistently showed the most pronounced protective effects across all disorders. Additionally, a significant reduction in all-cause mortality was observed (HR = 0.525, 95 %CI = 0.493-0.558). CONCLUSION: This study provides evidence that the effects of GLP-1 receptor agonists may extend beyond their known metabolic and cardioprotective benefits to include neuroprotection, associated with a decreased risk of developing various neurodegenerative disorders. These findings suggest the potential for expanding the therapeutic applications of GLP-1 receptor agonists to improve neurocognitive outcomes. Further research is warranted to elucidate the mechanisms underlying these neuroprotective effects and to explore their clinical applications in neurodegenerative disease prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
A global federated real-world data and analytics platform for research
Palchuk, M. B., London, J. W., Perez-Rey, D., Drebert, Z. J., Winer-Jones, J. P., Thompson, C. N., Esposito, J., & Claerhout, B. (2023) · JAMIA Open · doi:10.1093/jamiaopen/ooad035 · Cited by 948
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications
Caturano, A., D’Angelo, M., Mormone, A., Russo, V., Mollica, M. P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080420 · Cited by 579
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
The benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Research works printed but not linked: 32
- Lamptey, 2022, A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics, Int. J. Mol. Sci., 23, 10.3390/ijms23031851 · DOI · Paper page
- Aarsland, 2021, Parkinson disease-associated cognitive impairment, Nat. Rev. Dis. Primers, 7, 47, 10.1038/s41572-021-00280-3 · DOI · Paper page
- Ng, 2025, Mitochondrial therapeutics and mitochondrial transfer for neurodegenerative diseases and aging, Neural Regen. Res., 20, 794, 10.4103/NRR.NRR-D-23-02106 · DOI
- Procaccini, 2016, Role of metabolism in neurodegenerative disorders, Metabolism, 65, 1376, 10.1016/j.metabol.2016.05.018 · DOI · Paper page
- Ezkurdia, 2023, Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance, Int. J. Mol. Sci., 24, 10.3390/ijms24054354 · DOI
- Mulvaney, 2020, GLP-1 receptor agonists for Parkinson's disease, Cochrane Database Syst. Rev., 7, Cd012990
- Elbassuoni, 2019, Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes, Neurochem. Int., 131, 10.1016/j.neuint.2019.104583 · DOI · Paper page
- Yang, 2017, The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders, Int. J. Mol. Sci., 18, 10.3390/ijms18091861 · DOI
- Salcedo, 2012, Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders, Br. J. Pharmacol., 166, 1586, 10.1111/j.1476-5381.2012.01971.x · DOI · Paper page
- Verma, 2024, Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease, Eur. J. Pharmacol., 982, 10.1016/j.ejphar.2024.176936 · DOI
- Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models, Neuropharmacology, 136, 251, 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
- Gault, 2018, GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes, Peptides, 100, 101, 10.1016/j.peptides.2017.11.017 · DOI
- Ashok, 2022, Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation, Antioxidants (basel), 11
- Lee, 2021, The Role of Microglia in the Development of Neurodegenerative Diseases, Biomedicines, 9, 10.3390/biomedicines9101449 · DOI
- Wang, 2024, Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice, J. Biomed. Sci., 31, 38, 10.1186/s12929-024-01025-6 · DOI
- Delrue, 2024, Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management, Int. J. Mol. Sci., 25, 10.3390/ijms25179351 · DOI
- Antmen, 2024, Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior, Biomedicines, 12, 10.3390/biomedicines12102205 · DOI
- Dierssen, 2021, Editorial: Brain Insulin Resistance in Neurodevelopmental and Neurodegenerative Disorders: Mind the Gap!, Front. Neurosci., 15, 10.3389/fnins.2021.730378 · DOI
- Møller, 2023, Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes, Biomedicines, 11, 10.3390/biomedicines11113084 · DOI
- Andrade, 2024, Brain insulin resistance and Alzheimer's disease: a systematic review, Dement Neuropsychol, 18, e20230032, 10.1590/1980-5764-dn-2023-0032 · DOI
- Jyotsna, 2023, Exploring the Complex Connection Between Diabetes and Cardiovascular Disease: Analyzing Approaches to Mitigate Cardiovascular Risk in Patients With Diabetes, Cureus, 15, e43882
- Rajagopal, 2024, Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: an Updated Narrative Review, Cureus, 16, e65910
- J. Huang, F. Wu, L. Chen, J. Yu, W. Sun, Z. Nie, H. Liu, F. Yang, C. Zheng, CT-Based Radiomics Helps to Predict Residual Lung Lesions in COVID-19 Patients at Three Months after Discharge, Diagnostics (Basel) 11(10) (2021). · DOI
- Park, 2022, Efficacy and Optimal Pressure of Continuous Positive Airway Pressure in Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer, Cancers, 14, 10.3390/cancers14174308 · DOI
- Sergesketter, 2022, The Association Between Metabolic Derangement and Wound Complications in Elective Plastic Surgery, J. Surg. Res., 278, 39, 10.1016/j.jss.2022.03.017 · DOI
- Chen, 2018, Effects of polysaccharides from the base of Flammulina Velutipes stipe on growth of murine RAW264.7, B16F10 and L929 cells, Int J Biol Macromol 107(Pt b), 2150, 10.1016/j.ijbiomac.2017.10.090 · doi:10.1016/j.ijbiomac.2017.10.090
- Zingariello, 2022, Resident Self-Tissue of Pro-inflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Gata1(low) Mice, Biomolecules, 12, 10.3390/biom12020234 · DOI
- Haque, 2022, Metastatic renal cell carcinoma presenting as subcutaneous nodule, Radiol Case Rep, 17, 1973, 10.1016/j.radcr.2022.03.055 · doi:10.1016/j.radcr.2022.03.055
- Almaraz-Ortiz, 2022, Divergent copper-catalyzed syntheses of 3-carboxylpyrroles and 3-cyanofurans from O-acetyl oximes and β-ketoesters/nitriles, RSC Adv., 12, 26673, 10.1039/D2RA04938D · doi:10.1039/d2ra04938d
- Koshatwar, 2023, Exploring the Potential of Anti-diabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review, Cureus, 15, e44763
- D. Kothandan, D.S. Singh, G. Yerrakula, B. D, P. N, B.V. Santhana Sophia, R. A, S. Ramya Vg, K. S, J. M, Advanced Glycation End Products-Induced Alzheimer's Disease and Its Novel Therapeutic Approaches: A Comprehensive Review, Cureus 16(5) (2024) e61373. · DOI
- Khan, 2018, Role of islet peptides in beta cell regulation and type 2 diabetes therapy, Peptides, 100, 212, 10.1016/j.peptides.2017.11.014 · DOI
Cited by
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Metadata
- Authors
- Siddeeque, N., Hussein, M. H., Abdelmaksoud, A., Bishop, J., Attia, A. S., Elshazli, R. M., Fawzy, M. S., & Toraih, E. A.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 3
- Pages
- 113537
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403972995
- Cited by
- 103
- References
- 12
- FWCI
- 27.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.